Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor — scientific infographic poster

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract, arising from the interstitial cells of Cajal — the pacemaker cells that coordinate gastrointestinal (GI) motility. Once considered uniformly fatal in advanced disease, GIST was transformed into a manageable chronic condition by the discovery of its molecular driver (KIT mutations) and the introduction of imatinib mesylate in 2001 — one of the first and most dramatic examples of targeted cancer therapy in oncology. Today, the disease serves as a model for precision medicine, with treatment selection guided by the specific mutation subtype in every patient.

Table of Contents

  1. Overview
  2. Cell of Origin
  3. Molecular Drivers
  4. Clinical Presentation
  5. Diagnosis & Pathology
  6. Risk Stratification
  7. Treatment: Localized Disease
  8. Treatment: Metastatic Disease
  9. Prognosis & Survival
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Overview

Gastrointestinal stromal tumors are soft-tissue sarcomas that arise from the mesenchyme — the connective-tissue layer of the gastrointestinal wall — rather than from the mucosal epithelium like adenocarcinomas. They account for roughly 80% of all gastrointestinal mesenchymal tumors and are estimated to occur in 10–15 per million people per year in the United States, representing approximately 5,000–6,000 new diagnoses annually. GISTs can occur anywhere in the gastrointestinal tract from the esophagus to the rectum, and very rarely in extra-GI sites such as the omentum, mesentery, and retroperitoneum.

The stomach is the most common site, accounting for 50–60% of cases, followed by the small intestine (20–30%), colorectum (5–10%), esophagus (less than 5%), and extra-GI locations (rare). The anatomical location matters clinically: gastric GISTs tend to have a more favorable prognosis than small-intestinal GISTs of equivalent size and mitotic rate, likely reflecting differences in tumor biology and the immunological milieu rather than purely anatomical factors.

Before 2001, advanced GIST carried a median survival of fewer than 18 months and was essentially chemotherapy-resistant — conventional cytotoxic regimens for soft-tissue sarcoma achieved response rates under 5%. The identification of KIT gain-of-function mutations as the dominant oncogenic driver by Hirota et al. in 1998, followed by the landmark clinical trials of imatinib mesylate published in 2001–2002, fundamentally changed the prognosis. Imatinib produced objective tumor responses in over 50% of metastatic GIST patients and disease control in over 80%, extending median survival from under 18 months to over 5 years for patients who respond to first-line therapy.

GIST remains biologically heterogeneous. While most tumors harbor activating mutations in KIT or PDGFRA, a clinically distinct subset — "wildtype" GIST — lacks these mutations and frequently occurs in younger patients, women, and those with germline predisposition syndromes. The management of each molecular subtype has become increasingly individualized as successive generations of kinase inhibitors have entered practice.

Back to Table of Contents

Cell of Origin: Interstitial Cells of Cajal

GISTs arise from, or differentiate along the lineage of, the interstitial cells of Cajal (ICC) — a specialized population of mesenchymal cells distributed throughout the gastrointestinal wall that function as the pacemaker cells of gastrointestinal smooth muscle. The ICCs generate the slow-wave electrical rhythms that drive coordinated peristalsis and mediate neurotransmission between enteric motor neurons and smooth muscle cells. They form a three-dimensional network within the myenteric plexus and between the circular and longitudinal muscle layers.

The ICC lineage is defined by constitutive expression of three molecular markers that are central to the diagnosis of GIST:

The evidence that GISTs originate from ICCs or ICC precursors rests on: (1) the shared molecular signature (KIT+, DOG1+, CD34+); (2) ultrastructural similarities between GIST cells and ICCs (dense granules, cell processes, gap junctions); (3) the normal physiological requirement for KIT signaling in ICC development (mice with KIT loss-of-function mutations lack ICCs entirely); and (4) the gain-of-function KIT mutations found in GISTs recapitulate the constitutive KIT activation needed for ICC pacemaker activity. It is likely that KIT-activating mutations in ICC progenitors drive transformation, whereas the tumor cells then retain ICC-lineage markers throughout their development.

Back to Table of Contents

Molecular Drivers

GIST is one of the most molecularly well-characterized solid tumors. In most patients, a single driver mutation in one of a small number of genes determines the biological behavior and, critically, the response to specific tyrosine kinase inhibitors. Mutation testing is now considered mandatory before initiating systemic therapy.

KIT Mutations (75–80% of GISTs)

KIT encodes the KIT receptor tyrosine kinase. Normally, KIT requires binding of its ligand stem cell factor (SCF) to dimerize and autophosphorylate, activating downstream signaling pathways including RAS/MAPK, PI3K/AKT, and STAT3/5. In GIST, gain-of-function mutations cause ligand-independent, constitutive KIT activation — the kinase is permanently "on," driving uncontrolled cell proliferation and survival.

PDGFRA Mutations (10% of GISTs)

PDGFRA encodes platelet-derived growth factor receptor alpha, a structurally related receptor tyrosine kinase on chromosome 4q12 adjacent to KIT. PDGFRA-mutant GISTs tend to arise preferentially in the stomach, show epithelioid cell morphology, have lower mitotic rates, and behave more indolently than KIT-mutant GISTs of equivalent size.

Wildtype GIST (10–15%)

GISTs lacking KIT or PDGFRA mutations are classified as "wildtype" and comprise a heterogeneous group with distinct clinical and pathological features. They are more common in children, young adults, and women (in whom they may arise in the syndromic setting), and tend to cluster in the stomach.

Back to Table of Contents

Clinical Presentation

The clinical presentation of GIST is highly variable and depends on tumor size, location, and whether the tumor grows intraluminally (into the gastrointestinal lumen), exophytically (outward from the gastrointestinal wall), or endophytically within the wall. Small GISTs — particularly those in the stomach — are often clinically silent and are discovered incidentally on endoscopy performed for unrelated reasons such as evaluation of reflux, Barrett esophagus surveillance, or dyspepsia.

Incidental Discovery: With the widespread use of upper endoscopy and cross-sectional imaging, incidental gastric GISTs smaller than 2 cm are increasingly identified. These are usually submucosal lesions with intact overlying mucosa and smooth contours on endoscopy; the endoscopic appearance alone cannot reliably distinguish GIST from leiomyoma, schwannoma, or lipoma, making endoscopic ultrasound (EUS) and tissue sampling essential for characterization.

Symptomatic Presentations:

Metastatic patterns: GIST spreads hematogenously, most commonly to the liver (in 50–65% of metastatic cases) and peritoneum. Lymph node metastases are rare in KIT/PDGFRA-mutant GIST (unlike most carcinomas), which has important implications for surgical technique — lymph node dissection adds morbidity without benefit. Lung and bone metastases occur but are uncommon.

Back to Table of Contents

Diagnosis & Pathology

The diagnosis of GIST requires tissue biopsy with histological examination and immunohistochemical staining. Imaging is essential for staging and surgical planning but cannot provide a tissue diagnosis.

Imaging

Contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis is the standard imaging modality for staging. GISTs typically appear as well-defined, hypervascular solid masses arising from the gastrointestinal wall with avid arterial-phase enhancement. Larger tumors commonly show central necrosis, cystic degeneration, and heterogeneous attenuation. The hypervascular blush distinguishes GIST from most gastrointestinal carcinomas (which are hypovascular). Metastatic deposits in the liver are also typically hypervascular. PET-CT adds metabolic assessment and is valuable for early response monitoring — imatinib-responding tumors often show dramatic FDG-PET responses within days of treatment initiation, long before computed tomography shows a change in tumor size.

Endoscopy and Endoscopic Ultrasound (EUS): Upper endoscopy visualizes the overlying mucosa and can identify the submucosal origin and surface ulceration of GIST. EUS characterizes the wall layer of origin (fourth layer — muscularis propria — for most GISTs, distinguishing them from submucosal lipomas which arise in the third layer), internal echogenicity, and size. EUS-guided fine-needle aspiration (EUS-FNA) or biopsy allows tissue sampling for histology and IHC, particularly for gastric GISTs when percutaneous computed tomography-guided biopsy would risk peritoneal seeding.

Biopsy and Histology

GISTs most commonly show one of three histological patterns:

Immunohistochemistry (IHC)

IHC is the cornerstone of GIST diagnosis. The standard panel includes:

Molecular Testing

Mutation analysis of KIT (exons 9, 11, 13, 17) and PDGFRA (exons 12, 14, 18) is now standard of care for all GISTs requiring systemic therapy. The specific mutation determines the choice and dose of tyrosine kinase inhibitor. For KIT/PDGFRA wildtype cases, extended panel testing including SDHA/B/C/D, NF1, BRAF, and RAS is used to identify actionable alterations and inform prognosis.

Back to Table of Contents

Risk Stratification

Not all GISTs behave the same way. Small GISTs — particularly those smaller than 2 cm in the stomach — almost never metastasize, while large GISTs with high mitotic activity carry a high risk of recurrence even after complete surgical resection. Accurately stratifying risk is essential for deciding who needs adjuvant systemic therapy after curative-intent surgery.

The U.S. National Institutes of Health (NIH)/Fletcher consensus criteria (2002), subsequently modified by Miettinen and Lasota (2006) incorporating anatomical site, provide the most widely used stratification system. Risk is classified based on two primary variables:

Risk categories (gastric GIST):

Site effect: Non-gastric location independently worsens prognosis at any given size/mitotic combination. A 5 cm small-intestinal GIST with mitotic rate <5/50 HPF carries a much higher metastatic risk (~24%) than a comparable gastric GIST (~4%). This anatomical modifier is incorporated into the Miettinen/Lasota contour maps, which provide more granular risk estimates than the four-category U.S. National Institutes of Health system.

Tumor rupture is an independent high-risk factor regardless of size or mitotic rate. Rupture — whether spontaneous, at surgery, or from iatrogenic perforation during biopsy — spills tumor cells into the peritoneal cavity and dramatically increases the risk of peritoneal recurrence. Some guidelines consider ruptured GIST equivalent to metastatic disease in terms of the indication for indefinite imatinib therapy rather than adjuvant-duration treatment.

Exon 11 deletion type: Within high-risk GISTs, the specific KIT exon 11 mutation subtype provides additional prognostic information. Deletions encompassing codons 557–558 are associated with particularly high recurrence risk and may warrant extended or indefinite adjuvant imatinib duration in future clinical trials.

Back to Table of Contents

Treatment: Localized Disease

Surgery is the only potentially curative treatment for localized GIST, and the operative principles differ in important ways from the management of carcinomas at the same anatomical sites.

Surgery

Goal: Complete macroscopic resection with negative histological margins (R0). The target negative margin width is debated; because GISTs grow by expansion rather than infiltration, close margins (<1 cm) may still be oncologically adequate provided there is no gross residual tumor and no tumor rupture. Pseudocapsule preservation — avoiding rupture of the tumor's fibrous capsule during manipulation — is more important than achieving a wide soft-tissue margin.

No lymph node dissection: Unlike carcinomas arising at the same anatomical sites (gastric adenocarcinoma, colorectal cancer), KIT/PDGFRA-mutant GISTs virtually never metastasize to regional lymph nodes. Systematic lymphadenectomy adds morbidity without oncological benefit and is not performed. This is one of the most operationally important distinctions when surgeons accustomed to gastrointestinal oncology operate on GISTs.

Laparoscopic resection is appropriate for gastric and small-intestinal GISTs under 5 cm in accessible locations; outcomes equivalent to open surgery provided the tumor is not ruptured. Tumors larger than 5 cm at challenging locations (gastroesophageal junction, duodenum, rectum) often require open surgery or multidisciplinary planning.

Neoadjuvant Imatinib

For tumors that are technically resectable but where surgery would require extensive organ sacrifice (e.g., a large duodenal GIST requiring pancreaticoduodenectomy, a rectal GIST requiring abdominoperineal resection), pre-operative imatinib therapy can shrink the tumor and allow a less morbid operation. Neoadjuvant imatinib is administered for 6–12 months with response assessment every 2–3 months by computed tomography and/or positron emission tomography (PET); surgery is performed when maximal response has been achieved. Mutation testing before starting neoadjuvant therapy identifies PDGFRA D842V and NF1-associated GISTs, which do not respond; these go directly to surgery.

Adjuvant Imatinib

The American College of Surgeons Oncology Group (ACOSOG) Z9001 trial (DeMatteo et al., Lancet 2009) demonstrated that one year of adjuvant imatinib 400 mg/day after complete resection of KIT-positive GIST ≥3 cm improved recurrence-free survival compared to placebo (98% vs. 83% at 1 year). The subsequent Scandinavian Sarcoma Group/Arbeitsgemeinschaft Internistische Onkologie (SSG XVIII) trial (Joensuu et al., JAMA 2012) showed that 3 years of adjuvant imatinib was superior to 1 year for high-risk patients, improving 5-year recurrence-free survival (65.6% vs. 47.9%) and overall survival (92% vs. 81.7%). After 10 years of follow-up, overall survival was 79.0% with 3 years of imatinib and 65.3% with 1 year (hazard ratio 0.55), and the authors estimate that about half of the deaths in the first 10 years after surgery may be avoided with the longer treatment (Joensuu et al., JAMA Oncology 2020).

Based on these trials, 3 years of adjuvant imatinib is the current standard of care for high-risk GIST (high-risk per U.S. National Institutes of Health criteria). Adjuvant therapy is not standard practice for very-low or low-risk disease; evidence for intermediate-risk patients is less clear. An ongoing clinical question is whether 3 years is sufficient for very high-risk patients (tumor rupture, very large size with high mitotic rate) — some centers advocate 5 years or indefinite therapy in these cases. The IMADGIST randomized trial (Blay et al., Annals of Oncology 2024) tested 6 years against 3 years in 136 patients at high risk of relapse. At a median follow-up of 55 months, 3 more years of imatinib lowered relapse (hazard ratio 0.40), but time to imatinib resistance, survival, side effects and quality of life did not differ between the two groups.

Back to Table of Contents

Treatment: Metastatic and Unresectable Disease

The systemic treatment of metastatic GIST follows a line-therapy sequence of increasingly selective tyrosine kinase inhibitors, guided at each step by the mutation profile and the mechanism of resistance to prior therapy.

First-Line: Imatinib Mesylate

Imatinib, an orally bioavailable ABL/KIT/PDGFRA kinase inhibitor, is the cornerstone of first-line treatment for KIT-mutant metastatic GIST. The pivotal Phase II trial reported by Demetri et al. in the New England Journal of Medicine (2002) enrolled 147 patients with advanced GIST and achieved a partial response in 53.7% of patients and stable disease in a further 27.9% — a result unprecedented in soft-tissue sarcoma. Long-term follow-up of this trial reported a median survival of 57 months for all patients (Blanke et al., Journal of Clinical Oncology 2008), compared to fewer than 18 months with conventional chemotherapy.

The dose question has also been tested head to head. In the S0033 trial of 746 patients (Blanke et al., Journal of Clinical Oncology 2008), 400 mg and 800 mg daily gave similar results: median progression-free survival (time before the cancer grows) was 18 and 20 months, and median overall survival was 55 and 51 months, with no statistically significant differences and more severe side effects at the high dose. The MetaGIST analysis of 1,640 patients (Journal of Clinical Oncology 2010) found a small gain in progression-free survival with the high dose, essentially among patients with KIT exon 9 mutations, and no gain in overall survival.

Common imatinib toxicities include edema (periorbital, lower extremity), nausea, diarrhea, muscle cramps, and fatigue. Most are manageable and dose modification is rarely required. Serious toxicities (hepatotoxicity, severe myelosuppression) are uncommon.

Second-Line: Sunitinib

Sunitinib, a multi-targeted inhibitor of KIT, PDGFR, VEGFR, FLT3, and RET, is the standard second-line treatment after imatinib failure or intolerance. A Phase III randomized trial of 312 patients (Demetri et al., The Lancet 2006) demonstrated that sunitinib significantly improved time to tumor progression (median 27.3 vs. 6.4 weeks, hazard ratio 0.33) and overall survival compared to placebo following imatinib failure. Sunitinib is particularly active against secondary KIT exon 13 and 14 mutations, which are among the most common mechanisms of acquired imatinib resistance. It is less active against secondary exon 17/18 mutations. The standard dose is 50 mg/day for 4 weeks on, 2 weeks off, though continuous 37.5 mg/day dosing is increasingly used to reduce toxicity.

Third-Line: Regorafenib

Regorafenib, a broad-spectrum kinase inhibitor targeting KIT, PDGFR, VEGFR, RAF, and other kinases, demonstrated improved progression-free survival versus placebo (4.8 vs. 0.9 months, hazard ratio (HR) 0.27) in the GRID trial (Demetri et al., The Lancet 2013) after failure of both imatinib and sunitinib, establishing it as the third-line standard. Significant toxicities include hand-foot skin reaction, hypertension, and fatigue. The standard dose is 160 mg/day for 3 weeks on, 1 week off.

Fourth-Line: Ripretinib

Ripretinib is a switch-control kinase inhibitor that binds both the active and inactive conformations of KIT and PDGFRA, providing activity against a broad spectrum of primary and secondary resistance mutations. The INVICTUS trial (Blay et al., Lancet Oncology 2020) randomized patients who had received at least three prior lines of therapy to ripretinib 150 mg/day vs. placebo, demonstrating improved median progression-free survival (6.3 vs. 1.0 months, hazard ratio 0.15) and overall survival (15.1 vs. 6.6 months). Ripretinib was approved by the U.S. Food and Drug Administration in May 2020 as the fourth-line standard of care.

PDGFRA D842V-Specific: Avapritinib

Avapritinib was specifically designed to overcome the imatinib-resistance conferred by the PDGFRA D842V mutation. The NAVIGATOR trial (Heinrich et al., Lancet Oncology 2020) demonstrated an objective response rate of 88% (including 9% complete responses) in patients with PDGFRA D842V-mutant GIST — responses not achievable with any prior agent. Avapritinib was approved by the U.S. Food and Drug Administration in January 2020 as the first-ever treatment specifically for PDGFRA D842V GIST; the authors of the long-term NAVIGATOR analysis conclude it should be considered first-line therapy in this mutation subtype. The recommended dose for GIST on the FDA label is 300 mg/day. The label warns of serious bleeding inside the skull (intracranial hemorrhage), which occurred in 2.9% of 749 patients with GIST or advanced systemic mastocytosis, with fatal events in less than 1%, and it calls for stopping the drug permanently after any such bleed. The label warns of cognitive side effects too, in 33% of 995 patients across its uses; the long-term NAVIGATOR analysis reports cognitive effects in 32 of 56 patients (57%) with this mutation.

Newer Trials: Ripretinib Versus Sunitinib, and Bezuclastinib Plus Sunitinib

The INTRIGUE trial (Bauer et al., Journal of Clinical Oncology 2022) compared ripretinib with sunitinib after imatinib in 453 patients. Median progression-free survival was similar (8.0 vs. 8.3 months overall; not statistically significant), so ripretinib was not shown to be superior, with fewer severe side effects on ripretinib (41.3% vs. 65.6%).

A 2026 review of the PEAK trial (Italiano, Expert Opinion on Pharmacotherapy 2026) reports that adding bezuclastinib to sunitinib lengthened median progression-free survival from 9.2 to 16.5 months and raised objective response from 25.8% to 45.6%, with more severe side effects and more treatment changes. Approval was still pending in the review, whose literature search ran through 13 August 2026, and it lists mature survival results and long-term tolerability among the evidence gaps.

Resistance Mechanisms

Secondary resistance to imatinib develops in most patients over time through acquisition of additional mutations in the KIT kinase domain that sterically or allosterically interfere with imatinib binding. The most common secondary mutations occur in the adenosine triphosphate-binding pocket (exons 13–14) or the activation loop (exons 17–18). Because multiple resistant clones with different secondary mutations often coexist at the time of progression — clonal heterogeneity — no single second-line agent covers all possible resistance mutations, which explains the limited duration of benefit seen with sequential therapy.

Back to Table of Contents

Prognosis & Survival

The prognosis of GIST has been transformed by targeted therapy and is now strongly dependent on three factors: mutation status, risk group at presentation, and line of therapy at the time disease becomes incurable. The contrast between the pre-imatinib and post-imatinib eras represents one of the most striking improvements in the history of oncology for any solid tumor.

Localized GIST after surgery:

Metastatic GIST:

Prognostic factors in metastatic disease: Initial response to imatinib (partial response vs. stable disease), tumor burden, number of metastatic sites, and performance status are the strongest predictors of long-term outcome. Patients who achieve a complete metabolic response on positron emission tomography after imatinib, though rare, can have prolonged disease control exceeding a decade. Peritoneal dissemination carries a somewhat worse prognosis than liver-only metastases.

Wildtype GIST prognosis: SDH-deficient GISTs follow an indolent but persistently progressive course; long-term survivors are common even in metastatic disease, with some patients living 10–15 years after metastatic diagnosis despite imatinib resistance. NF1-associated multifocal small-intestinal GISTs are generally low-grade, rarely fatal from GIST itself, and managed expectantly unless symptomatic.

Back to Table of Contents

Key Research Papers

  1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472–80. — PubMed PMID: 12181401 · doi:10.1056/NEJMoa020461
  2. DeMatteo RP, Ballman KV, Antonescu CR, et al.; ACOSOG Z9001 investigators. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour. Lancet. 2009 Mar 28;373(9669):1097–104. — PubMed PMID: 19303137 · doi:10.1016/S0140-6736(09)60500-6
  3. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012 Mar 28;307(12):1265–72. — PubMed PMID: 22453568 · doi:10.1001/jama.2012.347
  4. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002 May;33(5):459–65. — PubMed PMID: 12094370 · doi:10.1053/hupa.2002.123545
  5. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998 Jan 23;279(5350):577–80. — PubMed PMID: 9438854 · doi:10.1126/science.279.5350.577
  6. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31;299(5607):708–10. — PubMed PMID: 12522257 · doi:10.1126/science.1079666
  7. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 1;26(4):626–32. — PubMed PMID: 18235122 · doi:10.1200/JCO.2007.13.4452
  8. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID). Lancet. 2013 Jan 26;381(9863):295–302. — PubMed PMID: 23177515 · doi:10.1016/S0140-6736(12)61857-1
  9. Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 Jul;21(7):935–46. — PubMed PMID: 32615108 · doi:10.1016/S1470-2045(20)30269-2
  10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006 May;23(2):70–83. — PubMed PMID: 17193820 · doi:10.1053/j.semdp.2006.09.001
  11. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011 Dec 22;11(12):865–78. — PubMed PMID: 22089421 · doi:10.1038/nrc3143
  12. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 1;26(4):620–5. — PubMed PMID: 18235121 · doi:10.1200/JCO.2007.13.4403
  13. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20;26(33):5360–7. — PubMed PMID: 18955451 · doi:10.1200/JCO.2008.17.4284
  14. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010 Mar 1;28(7):1247–53. — PubMed PMID: 20124181 · doi:10.1200/JCO.2009.24.2099
  15. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329–38. — PubMed PMID: 17046465 · doi:10.1016/S0140-6736(06)69446-4
  16. Blay JY, Serrano C, Heinrich MC, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Jul;21(7):923–934. — PubMed PMID: 32511981 · doi:10.1016/S1470-2045(20)30168-6
  17. Jones RL, Serrano C, von Mehren M, et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 Mar;145:132–142. — PubMed PMID: 33465704 · doi:10.1016/j.ejca.2020.12.008
  18. Joensuu H, Eriksson M, Sundby Hall K, et al. Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: an analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncol. 2020 Aug 1;6(8):1241–1246. — PubMed PMID: 32469385 · doi:10.1001/jamaoncol.2020.2091
  19. Blay JY, Schiffler C, Bouché O, et al. A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Ann Oncol. 2024 Dec;35(12):1157–1168. — PubMed PMID: 39241959 · doi:10.1016/j.annonc.2024.08.2343
  20. Bauer S, Jones RL, Blay JY, et al. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial. J Clin Oncol. 2022 Dec 1;40(34):3918–3928. — PubMed PMID: 35947817 · doi:10.1200/JCO.22.00294
  21. Italiano A. Evaluating bezuclastinib for the treatment of advanced gastrointestinal stromal tumours. Expert Opin Pharmacother. 2026 Sep;27(13):1417–1422. — PubMed PMID: 42690334 · doi:10.1080/14656566.2026.2721561

Search additional GIST literature: PubMed — Gastrointestinal Stromal Tumor

Back to Table of Contents

Connections

Back to Table of Contents